Navigation Links
Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity
Date:6/1/2008

Improvement Noted in Management of Transplant Recipients with Cancer

HERSHEY, Pa., June 1 /PRNewswire/ -- The management of immunosuppression in post-transplant patients with cancer is challenging. Clinicians must balance the need to treat the malignancy effectively while simultaneously monitoring the impact of chemotherapeutic agents on a patient's immune system.

Data relevant to improving management of such patients will be presented today at the American Transplant Congress in Toronto, Canada, from a cooperative study conducted by the Departments of Surgery and Pathology and the Division of Internal Medicine, Department of Medicine at the Penn State Milton S. Hershey Medical Center in Hershey, Pennsylvania.

Tadahiro Uemura, M.D., Ph.D. and his colleagues studied the immunosuppression status of 52 patients with post-transplant de novo malignancy, assessing the cell-mediated immunity of patients by taking advantage of the ability of the Cylex immune cell function assay (ImmuKnow(R)). They compared outcomes of patients who were and were not monitored using this assay over a follow-up period of nine months post-transplant. Their paper is entitled "Monitoring of immune function for treatment of post-transplant de novo malignancy." The 52 patients included 40 kidney transplants, 10 liver transplants, and two kidney and pancreas transplants. Uemura is an assistant professor, Division of Transplantation in the Department of Surgery at Penn State Hershey Medical Center.

The ImmuKnow cell function test measures cell-mediated immunity (CMI) by assaying the concentration of adenosine triphosphate (ATP) from CD4 cells following stimulation. The assay is intended for use in the detection of CMI in an immunosuppressed population.

According to Uemura and his collaborators, in patients previously diagnosed with cancer, levels of CMI were more precisely targeted toward 340 ng ATP/ml (within the "moderate" range of the ImmuKnow assay). However, for patients undergoing chemotherapy or radiation therapy for new malignancy post-transplant, there was a significant decrease in CMI despite a concurrent decrease in the levels of immunosuppressive medications. This suggests that patients' immune competencies change dramatically during active treatment of their cancer.

"It is clear that we can use the ImmuKnow cell function assay to manage immunosuppression more precisely in patients with new malignancy, post-transplant," stated Zakiyah Kadry, M.D., chief, Division of Transplantation, Department of Surgery and surgical director of the liver transplant program at Penn State Hershey Medical Center. "The test provides us with the ability to assess patients' immune status more accurately than the traditional monitoring of patients' levels of immunosuppressive drugs." she continued. Dr. Kadry is the senior author of this presentation.

About Penn State Milton S. Hershey Medical Center

Penn State Hershey Medical Center is one of the leading teaching and research hospitals in the country. The 501-bed Medical Center is a provider of high-level, patient-focused medical care. Annually the Medical Center admits more than 26,000 patients, accepts more than 766,000 outpatient visits, receives nearly 48,000 patients for emergency room visits and performs more than 23,000 surgical procedures. The Medical Center campus also includes Penn State College of Medicine (Penn State University's medical school), Penn State Hershey Cancer Institute, and Penn State Hershey Children's Hospital -- the region's only children's hospital.


'/>"/>
SOURCE Penn State Milton S. Hershey Medical Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
2. Prostate Cancer Treatment Offers Results Without Side Effects
3. New Gene Methylation Test for Prostate Cancer Available
4. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
5. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
6. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
7. Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Mens Health Week Is June 9-15)
8. Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool
9. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
10. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
11. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Shire plc (LSE: SHP, NASDAQ: ... Financial Officer, will present at the Deutsche Bank 41st Annual ... on Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... the Presentations and Webcasts section of Shire,s Investor website at ... be available on this same website for approximately 90 days. ...
(Date:4/27/2016)... 2016 Global  urinalysis market ... by 2022, according to a new report by ... http://photos.prnewswire.com/prnh/20150105/723757 ) , Automation ... and accuracy delivered by the new generation urinalysis ... urinalysis instruments and consumables. For instance, the automatic ...
(Date:4/26/2016)... April 26, 2016 Diplomat Pharmacy, Inc. (NYSE: ... Jennifer Hagerman , Pharm D., to Vice President of ... at Diplomat, Hagerman will continue to lead and oversee ... delivers custom education and training to Diplomat employees and ... industry. Diplomat University also houses the quality assurance department, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... 29, 2016 , ... The Wharton School of the ... Prize of the 2016 Wharton Business Plan Competition —as well as the ... and the Committee Award for Most ‘Wow Factor,’ making them the first team ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent ... cancer deaths. More than 10,000 people are expected to die of melanoma this year. The ... the one of the most commonly diagnosed cancers in young women. A recent breakthrough in ...
(Date:4/29/2016)... ... ... City based oral and maxillofacial surgeon Dr. Majid Jamali is an expert in ... apnea. Dr. Jamali is proud to offer this permanent solution to patients who suffer from ... bones. This surgery is performed to correct the alignment of the jaw. It is beneficial ...
Breaking Medicine News(10 mins):